Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by goldtechon Jan 09, 2022 1:36pm
243 Views
Post# 34297793

Looking forward

Looking forwardAfter years of Elliott and Gene screwing the shareholders we can look forward to some changes. First thing we need to eliminate Elliott totally, no consultant or any association with Promis, then his buddy Gene must go as well. This board needs some credible Directors, Wyman, Gregory, Kirwin and the do nothing head bobbers to Gene must be punted. Now we have pending news on serology and numerous antibodies to joint venture. This news is waiting to be released in this quarter, but Gene wants a rollback before the stock has a chance to appreciated, he is always a detriment to this company. Lots to happen this quarter but with an incompetent corrupt management I will tread cautiously.
<< Previous
Bullboard Posts
Next >>